Video Description
Welcome to Emerging Biotech: Today’s Insights Into Tomorrow’s Cancer Therapies.
I’m Jeff, Founder here at Oncoleader.
In this first episode, I’m examining Avenzo Therapeutics – a company that is absolutely poised to disrupt the industry.
Avenzo has raised over 550 million dollars in three funding rounds over the course of the last 2.5 years to advance their small molecule CDK2 inhibitor making them one of the most well-funded biotech startups in the world.
Founded in San Francisco, CA in 2022, Avenzo stands out to me for three key reasons:
First, its leadership: Two highly renowned scientists with a long list of successes are steering the ship.
Second, its financial backing: Avenzo has secured substantial funding – they’re absolutely loaded – providing a robust foundation for its ambitious goals.
Third, its promising, data-driven platform and strategic approach to patient selection has set them up for clinical and commercial success. With a strong scientific rationale as their guide, Avenzo has decided to focus on targeting CDK2-dependent cancers, primarily hormone receptor-positive breast cancer and CCNE1-amplified solid tumors, including ovarian cancer.
While they have not gathered any clinical data yet, their lead compound, AZVO-021, has shown promising single-agent and synergistic activity across multiple preclinical models and it appears to be very safe.
Join me as we dissect Avenzo’s science, strategy, and potential impact on the oncology landscape.
This is Emerging Biotech: Today’s Insights Into Tomorrow’s Cancer Therapies.
Links:
Link to Allorion’s data from 2022 poster – https://alloriontx.com/wp-content/uploads/2024/04/2022-April-AACR_ARTS-021-is-a-Potent-and-Selective-CDK2-Inhibitor-That-Demonstrates-Anti-cancer-Activity-in-Preclinical-Cancer.pdf
Link to Avenzo’s data from 2024 poster – https://avenzotx.com/wp-content/uploads/AVETMAGL24-486450-ESMO-Poster_Final87.pdf
Avenzo’s Phase 1/2 clinical trial – https://clinicaltrials.gov/study/NCT05867251
